Could Faricimab Data Help Roche Maintain Ophthalmic Market Foothold?
Executive Summary
The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.
You may also be interested in...
Roche Veteran Launches Biotech Aiming To Disrupt Eye Drug Market
Two veterans of the ophthalmology field are reuniting to launch a portfolio-based biotech company EyeBio.
Phase II Data May Be Good Sign For 8mg Aflibercept, But Will Payers Bite?
There are concerns that even with better efficacy and dosing versus Eylea and biosimilars, payers may impose step-edits on Regeneron’s new high-dose version.
Nine Major Approval Decisions To Watch In Early 2022
Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.